TMAO: Evidence-Based Ways to Improve This Number

What Is TMAO and Why Does It Matter?

Trimethylamine N-oxide is a small organic compound your body produces in two steps. Gut bacteria first convert dietary precursors (choline, L-carnitine, betaine) into trimethylamine (TMA). The liver enzyme flavin-containing monooxygenase 3 (FMO3) then oxidizes TMA into TMAO, which enters the bloodstream.

TMAO gained clinical attention after a 2011 study by Wang et al. used metabolomics screening in over 1,800 patients and identified TMAO as an independent predictor of cardiovascular disease 1. That initial finding has since been confirmed across multiple cohorts. A 2017 meta-analysis published in the Journal of the American Heart Association, pooling 19 prospective studies with 19,256 participants, found that each 10 µmol/L increase in TMAO was associated with a 7.6% increase in all-cause mortality risk 2. The association held after adjusting for traditional risk factors like LDL cholesterol, blood pressure, and smoking status.

What makes TMAO particularly relevant is its mechanistic role. TMAO promotes atherosclerosis by enhancing macrophage cholesterol accumulation, promoting foam cell formation, and increasing platelet hyperreactivity 3. It is not simply a bystander marker. Dr. Stanley Hazen, Chair of Cardiovascular and Metabolic Sciences at the Cleveland Clinic Lerner Research Institute, has stated: "TMAO is not just associated with heart disease risk; it directly participates in the disease process by altering cholesterol and sterol metabolism in multiple tissues" 1.

What Are Normal TMAO Levels?

Most clinical laboratories define a low-risk TMAO level as below 6.2 µmol/L. Values between 6.2 and 9.9 µmol/L are considered moderate risk. Levels at or above 10 µmol/L indicate elevated cardiovascular risk and warrant intervention.

These thresholds originate primarily from the Cleveland HeartLab reference ranges, validated in cohorts from the GeneBank study. In a 2013 study published in the New England Journal of Medicine, Tang et al. followed 4,007 patients undergoing elective coronary angiography for three years. Patients in the highest TMAO quartile (above 6.18 µmol/L) had a 2.54-fold increased risk of major adverse cardiovascular events compared to the lowest quartile 4. The hazard ratio remained significant (HR 1.43, 95% CI 1.05 to 1.94) even after adjusting for traditional risk factors and renal function.

Context matters with this test. TMAO levels fluctuate based on recent meals. A seafood-heavy dinner can spike TMAO transiently. For this reason, fasting morning specimens provide the most clinically useful readings. Chronic kidney disease also raises TMAO because renal clearance accounts for the majority of TMAO elimination 5. If your estimated GFR is reduced, an elevated TMAO may partly reflect impaired clearance rather than excess production.

Dietary Strategies to Lower TMAO

Diet is the most powerful lever. TMAO production depends on substrate availability, so reducing dietary precursors and shifting gut flora composition both contribute to lower levels.

Reduce red meat intake. Red meat is the richest dietary source of L-carnitine, the amino acid derivative that gut bacteria convert to TMA. A crossover trial by Koeth et al. (2019) assigned 113 participants to diets high in red meat, white meat, or non-meat protein for four weeks each. The red meat diet produced plasma TMAO levels roughly three times higher than the non-meat protein diet 6. The red meat diet also increased renal TMAO excretion and decreased fractional renal TMAO clearance, meaning the body became less efficient at removing TMAO when red meat intake was high.

Adopt a Mediterranean-style eating pattern. The PREDIMED trial (N=7,447) demonstrated cardiovascular benefits of Mediterranean diets rich in olive oil and nuts 7. Subsequent analyses of Mediterranean diet adherents show lower TMAO concentrations, likely because plant-dominant diets favor bacterial species that produce less TMA. A 2020 study in Gut found that a Mediterranean diet intervention shifted microbiome composition toward species associated with lower TMAO and reduced markers of frailty and inflammation 8.

Be strategic about eggs and fish. Eggs contain choline, a TMAO precursor, but the TMAO response to eggs is significantly smaller than to red meat. Fish contains preformed TMAO (not TMA), which the kidneys clear rapidly. A study by Cho et al. showed that while plasma TMAO spiked higher after fish consumption than after eggs or beef, it returned to baseline within 24 hours and did not trigger the same pro-atherogenic downstream signaling 9. Fish consumption does not need to be restricted for TMAO management purposes.

Gut Microbiome Interventions

The gut microbiome is the production factory for TMA. Changing which bacteria dominate your gut changes how much TMA (and subsequently TMAO) you produce. Two people eating identical diets can have very different TMAO levels based solely on their microbial composition.

Dietary fiber and prebiotics. Fiber-rich diets promote Bacteroidetes and reduce Firmicutes populations. This shift matters because certain Firmicutes species (including Clostridium and Anaerococcus) carry the TMA-lyase gene cluster (cutC/cutD) responsible for converting choline to TMA 10. A 2019 randomized controlled trial showed that supplementation with 16 g/day of arabinoxylan fiber for six weeks significantly reduced fasting TMAO by 40.6% compared to placebo in overweight adults 11.

Probiotics. Evidence here is early but directionally positive. Lactobacillus and Bifidobacterium strains do not carry TMA-lyase genes, and colonization with these species may competitively exclude TMA-producing bacteria. A 2021 randomized trial in Nutrients found that a multi-strain probiotic (containing L. acidophilus, B. lactis, and L. rhamnosus) reduced plasma TMAO by 29.3% over 12 weeks in participants with metabolic syndrome 12. Dr. W.H. Wilson Tang, a cardiologist at the Cleveland Clinic and co-author of several landmark TMAO studies, has noted: "Targeting the gut microbiome to reduce TMAO represents a promising therapeutic frontier, though we need larger trials before we can make definitive clinical recommendations" 4.

Fermented foods. Regular consumption of fermented foods (yogurt, kefir, kimchi, sauerkraut) has been associated with greater microbial diversity. A 2021 Stanford study published in Cell showed that a 10-week high-fermented-food diet increased microbiota diversity and decreased 19 inflammatory markers 13. While this study did not measure TMAO directly, increased microbial diversity is consistently associated with lower TMAO in observational data.

Supplements and Pharmacologic Agents

Several compounds have shown the ability to reduce TMAO in preclinical or early clinical research. None are FDA-approved specifically for TMAO reduction.

3,3-Dimethyl-1-butanol (DMB). DMB is a structural analog of choline that inhibits microbial TMA lyase enzymes. In a 2015 study published in Cell, Wang et al. demonstrated that DMB reduced plasma TMAO levels and inhibited atherosclerotic lesion development in ApoE-knockout mice fed a high-choline diet 14. DMB occurs naturally in some balsamic vinegars and cold-pressed extra virgin olive oils. Human clinical trials are ongoing, but no standardized DMB supplement is currently available.

Resveratrol. This polyphenol, found in grape skins and red wine, has shown TMAO-lowering effects in animal models. Chen et al. (2016) reported that resveratrol remodeled the gut microbiota in mice, increasing Lactobacillus and Bifidobacterium while decreasing TMA-producing genera, resulting in a 36% reduction in TMAO 15. Human data remain limited, and the doses required (250 to 500 mg/day) exceed what dietary grape consumption alone can provide. If supplementing, look for trans-resveratrol formulations with documented bioavailability data.

Berberine. This alkaloid, used in traditional Chinese medicine and available as a supplement, has demonstrated TMAO-lowering effects. A 2022 study in Theranostics found berberine at 500 mg twice daily reduced TMAO by 33.8% in patients with heart failure over 8 weeks 16. Berberine also lowers LDL cholesterol and fasting glucose, making it potentially useful in patients with overlapping metabolic risk factors. It can interact with CYP3A4-metabolized medications, so review drug interactions before starting.

Allicin (garlic-derived). Allicin and its metabolites reduce TMA production in vitro by inhibiting microbial TMA lyase activity. A 2016 study confirmed that diallyl disulfide from garlic reduced TMAO by approximately 32% in mice on a high-carnitine diet 17. Aged garlic extract (600 to 1,200 mg/day) is the most studied formulation. Human TMAO-specific trials are still needed.

Exercise and Lifestyle Factors

Physical activity may lower TMAO through indirect mechanisms, including changes to gut transit time, microbiome composition, and body composition.

A 2019 cross-sectional analysis within the PREDIMED-Plus trial (N=574) found that participants meeting WHO physical activity guidelines (150 minutes/week of moderate-intensity exercise) had 18.7% lower TMAO levels compared to sedentary participants, independent of dietary intake 18. The association was strongest for aerobic exercise rather than resistance training.

Body fat matters too. Visceral adiposity is associated with higher TMAO, potentially because adipose tissue inflammation alters gut permeability and microbiome composition. Weight loss of 5 to 10% of body weight has been associated with meaningful TMAO reductions in bariatric surgery cohorts, though it is difficult to separate the weight loss effect from the concurrent dietary changes 19.

Sleep quality is an emerging variable. Circadian disruption alters gut microbiome rhythmicity, and preliminary data suggest that shift workers have higher TMAO levels than day workers 20. Prioritizing consistent sleep timing (within a 1-hour window) may support microbiome stability.

Monitoring and Retesting Protocol

After implementing dietary and lifestyle changes, retest TMAO at 8 to 12 weeks. This interval allows sufficient time for gut microbiome remodeling, which typically requires four to six weeks of sustained dietary change to produce measurable shifts in metabolite output.

For the most accurate result, fast for 8 to 12 hours before the blood draw and avoid seafood for 24 hours prior (fish contains preformed TMAO that temporarily inflates readings). Morning draws between 7:00 and 10:00 AM reduce circadian variability.

Track your TMAO alongside other cardiovascular biomarkers. The combination of TMAO with high-sensitivity C-reactive protein (hs-CRP), lipoprotein(a), and apolipoprotein B provides a more complete picture of residual cardiovascular risk than any single marker. A 2018 analysis in the European Heart Journal found that adding TMAO to the Framingham Risk Score improved net reclassification by 8.6% for cardiovascular events 21.

If your TMAO remains above 6.2 µmol/L after 12 weeks of dietary intervention, consider adding one of the supplements described above (berberine or aged garlic extract have the most human data) and retest at another 8-week interval. Persistently elevated TMAO in the setting of good dietary adherence warrants evaluation of renal function, as an eGFR below 60 mL/min/1.73 m² significantly impairs TMAO clearance 5.